《多联疫苗临床试验技术指导原则》发布

Core Viewpoint - The National Medical Products Administration (NMPA) has released the "Technical Guidelines for Clinical Trials of Multivalent Vaccines" to support the high-quality development of the vaccine industry and accelerate the research and market launch of domestic multivalent vaccines [1] Group 1: Guidelines Overview - The guidelines include considerations for topic selection, clinical trial design, and post-marketing changes, specifically applicable to the clinical development of multivalent vaccines [1] Group 2: Importance of Multivalent Vaccines - Multivalent vaccines contain antigens related to different pathogens and are defined based on biological taxonomy by "species" [1] - These vaccines simplify immunization schedules, reduce the number of vaccinations required, and enhance the convenience and compliance of vaccination, which is crucial for increasing vaccination rates and alleviating public health burdens [1]